Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation

Recent studies suggest the possibility of a direct antiangiogenic effect of anti–epidermal growth factor receptor (EGFR) drugs due to the presence of EGFR on endothelial cells. The aim of this study was to analyze the direct effect on endothelial cells of associating EGFR targeting, vascular endothelial growth factor receptor (VEGFR)-2 targeting, and irradiation. We examined both the cytotoxic effects and the effect on molecular markers resulting from the combined action of gefitinib (Iressa; anti-EGFR), ZM317450 [VEGFR tyrosine kinase inhibitor (VTKI); anti-VEGFR-2], and irradiation (radiation therapy) on HMME7 cells, an immortalized microvascular endothelial cell of human origin. The presence of a functional EGFR pathway sensitive to gefitinib was shown in HMME7 cells (gefitinib-induced decrease in phospho-EGFR, phospho-p42/p44, and phospho-Akt). The stimulation of VEGFR-2 pathway led to an increase in Akt phosphorylation that was inhibited by VTKI. Of note, a post–radiation therapy induction of phospho-p42/p44 was observed on HMME7 cells, and this effect was inhibited by a pretreatment with gefitinib. Based on combination indexes (Chou and Talalay analyses), the associations gefitinib-radiation therapy, VTKI-radiation therapy, VTKI-gefitinib, and gefitinib-VTKI-radiation therapy were found to be additive, slightly synergistic, and markedly synergistic, respectively, for the cytotoxicity on HMME7 cells. Among molecular explanatory factors that were examined, the combination gefitinib-radiation therapy totally abolishes DNA-dependent protein kinase expression, and gefitinib attenuates the radiation therapy–induced enhancement of ERCC1 and augments the VTKI-induced CD95 enhancement. The existence of a radiation therapy–dependent neoangiogenesis may be related to the induction of EGFR pathway in endothelial cells, a phenomenon that can be attenuated by anti-EGFR drugs like gefitinib. In complement to the direct antitumor effects of radiation therapy and anti-EGFR drugs, a strong antiangiogenic effect may be obtained with therapeutic strategies combining radiation therapy with EGFR and VEGFR-2 targeting agents. [Mol Cancer Ther 2005;4(12):1962–71]

[1]  D. Hallahan,et al.  Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Carlos Arteaga,et al.  Targeting HER1/EGFR: a molecular approach to cancer therapy. , 2003, Seminars in oncology.

[3]  G. Tortora,et al.  Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M. Kuwano,et al.  Induction of human microvascular endothelial tubular morphogenesis by human keratinocytes: involvement of transforming growth factor-alpha. , 1992, Biochemical and biophysical research communications.

[5]  J. Pouysségur,et al.  Complete Structure of an Increasing Capillary Permeability Protein (ICPP) Purified from Vipera lebetina Venom , 2002, The Journal of Biological Chemistry.

[6]  A. Harris,et al.  Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. , 2001, Anticancer research.

[7]  G. Fontanini,et al.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  C. Bucana,et al.  Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade , 2004, Cancer Research.

[9]  J. Tonn,et al.  Characteristic gene expression profile of primary human cerebral endothelial cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  B. Telfer,et al.  ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy , 2004, Clinical Cancer Research.

[11]  J. Debus,et al.  SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. , 2003, Cancer research.

[12]  F. D'armiento,et al.  Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. , 2004, Molecular cancer therapeutics.

[13]  D. Hochhauser,et al.  Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) , 2004, Clinical Cancer Research.

[14]  J. Bond,et al.  Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Johnston,et al.  The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. , 2003, Seminars in oncology.

[16]  K. Subbaramaiah,et al.  Regulation of Cyclooxygenase-2 by Interferon γ and Transforming Growth Factor α in Normal Human Epidermal Keratinocytes and Squamous Carcinoma Cells , 1999, The Journal of Biological Chemistry.

[17]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[18]  J. Chou,et al.  Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Kuwano,et al.  Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib (‘Iressa’, ZD1839) , 2004, Cancer science.

[20]  N. Magné,et al.  Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil , 2003, British Journal of Cancer.

[21]  D. Wong,et al.  Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Upregulates p27KIP1 and p15INK4B and Induces G1 Arrest in Oral Squamous Carcinoma Cell Lines , 2002, Oncology.

[22]  I. Fidler,et al.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.

[23]  Kai Chen,et al.  c-Jun N-terminal Kinase Activation by Hydrogen Peroxide in Endothelial Cells Involves Src-dependent Epidermal Growth Factor Receptor Transactivation* , 2001, The Journal of Biological Chemistry.

[24]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[25]  G. Tortora,et al.  Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy , 2004, Clinical Cancer Research.

[26]  R. Schmidt-Ullrich,et al.  Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. , 1996, Radiation research.

[27]  D. Hallahan,et al.  Ionizing radiation regulates expression of the c-jun protooncogene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Kuwano,et al.  ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. , 2002, Cancer research.

[29]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Manuel Hidalgo,et al.  Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.

[31]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[32]  E. Dmitrovsky,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers , 2004, Clinical Cancer Research.

[33]  C. Dinney,et al.  Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  G. Prendergast.  Molecular cancer therapeutics : strategies for drug discovery and development , 2005 .

[35]  Jean-Luc Balligand,et al.  Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. , 2003, Cancer research.

[36]  L. Ellis,et al.  Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors , 2001, British Journal of Cancer.

[37]  T. Kivelä,et al.  Ocular complications after iodine brachytherapy for large uveal melanomas. , 2004, Ophthalmology.

[38]  K. Subbaramaiah,et al.  Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. , 1999, The Journal of biological chemistry.